Compare DAO & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAO | RLAY |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2019 | 2020 |
| Metric | DAO | RLAY |
|---|---|---|
| Price | $9.98 | $12.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.86 |
| AVG Volume (30 Days) | 52.6K | ★ 2.7M |
| Earning Date | 05-14-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | $12.15 | N/A |
| Revenue Next Year | $14.03 | $324.03 |
| P/E Ratio | $72.35 | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $6.30 | $1.82 |
| 52 Week High | $12.96 | $13.04 |
| Indicator | DAO | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 49.31 | 70.59 |
| Support Level | $8.48 | $9.16 |
| Resistance Level | $10.33 | N/A |
| Average True Range (ATR) | 0.51 | 0.76 |
| MACD | -0.05 | 0.21 |
| Stochastic Oscillator | 56.22 | 76.18 |
Youdao Inc develops and markets software applications. It engages in developing technologies to provide learning content, applications, and solutions. The firm operates in three segments: Learning services, Smart devices, and Online marketing services. The majority of its revenue comes from the Learning services segment, which generates revenues from online courses, mainly including Youdao Premium Courses, NetEase Cloud Classroom, and China University MOOC. The learning products segment includes sales of smart devices such as the Youdao Dictionary Pen and the Youdao Pocket Translator. Geographically, all of its revenue is generated from the People's Republic of China.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).